TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $2.47M rose 52.6% year over year, behind the +67.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 12.5% from the prior quarter. Over 3 fiscal years it compounded at +191.7% a year.
Context
- Stock-based compensation amounted to 20.2% of revenue in FY2025, up 1.7 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +52.6% toward the trailing-twelve-month pace of +67.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 9.13M USD
- Year-over-year change
- +67.8%
- 4-year CAGR
- +202.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.13M | +67.8% |
| FY2024 | 2024-12-31 | 5.44M | +288.1% |
| FY2023 | 2023-12-31 | 1.4M | +281.0% |
| FY2022 | 2022-12-31 | 368K | +237.6% |
| FY2021 | 2021-12-31 | 109K | — |
Stock-Based Compensation vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's LTM Mar 2026 stock-based compensation of $9.98M is the 2nd largest of the 11 companies compared; the peer median is $4.33M.
- Its year-over-year change of +67.1% is the 2nd highest of 11, against a peer median of -7.1%.
- Stock-based compensation amounts to 22.2% of revenue for TLSI, versus a peer median of 19.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.18M | +38.7% | -10.1% | 10.4% | |
| LTM Mar 2026 | $9.98M | +67.1% | +191.7% | 22.2% | |
| LTM Mar 2026 | $9.42M | +38.0% | +88.2% | 1524.4% | |
| LTM Mar 2026 | $5.55M | +98.0% | +9.0% | 29.4% | |
| LTM Mar 2026 | $5.4M | -5.3% | -7.8% | 3.6% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $4.48M | -15.1% | +38.4% | 241.9% |
| LTM Dec 2025 | $4.19M | -42.3% | -39.2% | 32.2% | |
| LTM Mar 2026 | $2.9M | -7.5% | -5.6% | 98.2% | |
| LTM Mar 2026 | $2.49M | -6.7% | -22.0% | 4.3% | |
| LTM Mar 2026 | $706K | -76.8% | — | 2.2% | |
| LTM Mar 2026 | $141K | -98.0% | — | 0.1% | |
| Peer median (excluding TLSI) | $4.33M | -7.1% | -6.7% | 19.9% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.85M) | (47.19M) | (59.36M) | (30.05M) | (39.23M) |
| Depreciation & Amortization | 464K | 398K | 684K | 744K | 626K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 109K | 368K | 1.4M | 5.44M | 9.13M |
| Change in Working Capital | (131K) | 2.3M | 537K | (9.55M) | 2.07M |
| Accounts Receivables | (741K) | (200K) | (1.98M) | (1.72M) | (1.63M) |
| Inventory | (725K) | (179K) | (1.07M) | (1.5M) | 971K |
| Accounts Payables | 3.18M | 5.25M | 2.84M | (4.38M) | 2.02M |
| Other Working Capital | (1.84M) | (2.57M) | 751K | (1.94M) | 711K |
| Other Non-Cash Items | 5.71M | 11.81M | 6.16M | (7.43M) | 9.39M |
| Operating Cash Flow | (22.7M) | (32.31M) | (50.58M) | (40.84M) | (18.01M) |
| Capital Expenditures | (1.26M) | (786K) | (588K) | (345K) | (918K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 80K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1.16M) | (1.13M) | (1M) | 0 | 0 |
| Investing Cash Flow | (2.26M) | (1.79M) | (1.59M) | (345K) | (838K) |
| Debt Repayment | (1.3M) | (131K) | (87K) | 24.92M | 9.92M |
| Common Stock Issued | 0 | 0 | 0 | 15.54M | 22.91M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54K | 94K | 45.53M | (2.52M) | (2.07M) |
| Financing Cash Flow | 50.77M | 13.46M | 54.63M | 37.94M | 30.76M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.81M | (20.64M) | 2.46M | (3.25M) | 11.91M |
| Free Cash Flow | (23.96M) | (33.1M) | (51.17M) | (41.19M) | (18.93M) |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.